Abstract

Pf38 is a surface protein of the malarial parasite Plasmodium falciparum. In this study, we produced and purified recombinant Pf38 and a fusion protein composed of red fluorescent protein and Pf38 (RFP-Pf38) using a transient expression system in the plant Nicotiana benthamiana. To our knowledge, this is the first description of the production of recombinant Pf38. To verify the quality of the recombinant Pf38, plasma from semi-immune African donors was used to confirm specific binding to Pf38. ELISA measurements revealed that immune responses to Pf38 in this African subset were comparable to reactivities to AMA-1 and MSP119. Pf38 and RFP-Pf38 were successfully used to immunise mice, although titres from these mice were low (on average 1∶11.000 and 1∶39.000, respectively). In immune fluorescence assays, the purified IgG fraction from the sera of immunised mice recognised Pf38 on the surface of schizonts, gametocytes, macrogametes and zygotes, but not sporozoites. Growth inhibition assays using αPf38 antibodies demonstrated strong inhibition (≥60%) of the growth of blood-stage P. falciparum. The development of zygotes was also effectively inhibited by αPf38 antibodies, as determined by the zygote development assay. Collectively, these results suggest that Pf38 is an interesting candidate for the development of a malaria vaccine.

Highlights

  • Malaria continues to be a major health burden worldwide

  • In order to investigate the suitability of Pf38 as a malaria vaccine, we produced Pf38 and a fusion protein composed of red fluorescent protein and Pf38 (RFPPf38)

  • Production and purification of Pf38 and RFP-Pf38 The DNA-sequences coding for Pf38 and RFP-Pf38 were cloned into the plant expression vector pTRAkc [23]

Read more

Summary

Introduction

Malaria continues to be a major health burden worldwide. In 2010, 216 million estimated cases and 655.000 deaths from malaria were reported. Ninety-one percent of these malaria cases were due to infection with P. falciparum [1]. Current efforts to control malaria, including insecticide-treated mosquito nets, spraying of long-lasting insecticides [2] and artemisinin-based combination therapy as a first treatment [3], diminish malaria incidence but continue to leave a high burden of this disease in sub-Saharan areas [4]. Imperfect diagnostics and self-medication [5] have led to inaccurate data collection and an underestimation of malaria cases. Resistance among malaria vectors (e.g., resistance to pyrethroid insecticides) has been detected in many countries in sub-Saharan Africa [6], indicating that moderately effective measures today could become useless in the future

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.